SCHEMBL2748698

SCHEMBL2748698

COC(=O)Cn1cc(I)cn1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.39
HSD17B10 Q99714 3/20 0.39
ALDH1A1 P00352 1/20 0.39
SYK P43405 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.37
FAAH O00519 1/20 0.35
KMT2A Q03164 1/20 0.35
AR P10275 1/20 0.34
CTSK P43235 1/20 0.34
CTSC P53634 1/20 0.34
KAT2B Q92831 1/20 0.34
NPC1 O15118 2/20 0.34
GAA P10253 1/20 0.34
TP53 P04637 1/20 0.34
RAB9A P51151 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
ALPI P09923 1/20 0.33
ALPG P10696 1/20 0.33
PLAA Q9Y263 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14125781 0.83 GSK3A (0.44) KDM4EALDH1A1SMN1; SMN2KMT2A
SCHEMBL2749841 0.83 L3MBTL1 (0.38) KDM4EHSD17B10ALDH1A1SMN1; SMN2KMT2A
SCHEMBL24883514 0.82 KDM4E (0.43) KDM4EALDH1A1KMT2AARALPI
SCHEMBL22557430 0.81 TSHR (0.41) ALDH1A1KMT2AKAT2BL3MBTL1
SCHEMBL17382262 0.81 CCNC (0.43) ARRAB9A
SCHEMBL11983555 0.81 ALPI (0.50) KDM4EHSD17B10ALDH1A1SYKSMN1; SMN2
SCHEMBL12017379 0.80 SMN1; SMN2 (0.38) ALDH1A1SMN1; SMN2KMT2AARNPC1
SCHEMBL16876215 0.80 HSD17B10 (0.40) KDM4EHSD17B10ALDH1A1SMN1; SMN2KMT2A
SCHEMBL13739798 0.79 MEN1 (0.42) KDM4EHSD17B10ALDH1A1SYKSMN1; SMN2
SCHEMBL1140333 0.79 ALDH1A1 (0.46) KDM4EHSD17B10ALDH1A1SYKSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
EP-2265270-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009099982-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 KDM4E 1371/4885HSD17B10 4249/4885ALDH1A1 945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.